We identify TOP2B upregulation as a key driver of cardiotoxicity and demonstrate that ASO therapy targeting TOP2B prevents heart failure and improves survival in preclinical models, providing a promising strategy to protect patients with cancer during chemotherapy. Here, TOP2B is linked to heart failure.